Cell Free DNA accurately correlates with breast cancer DNA

Howard B. Urnovitz, Modulation of breast cancer cell-free DNA with surgical resection. J Clin Oncol 31, 2013 (suppl; abstr 11060)

Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center announced results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients at the American Society of Clinical Oncology Annual Meeting (ASCO 2013).

By | July 3rd, 2016|Medical publications|0 Comments

Clinica Highlights Chronix Biomedical’s Diagnostics

Tina Tan, Chronix’s new liquid biopsy approach show promise as early predictor of cancer therapies. Clinica, 18 April 2016.

A blood-based test which looks at chromosomal gains and losses in cell-free DNA (cfDNA) has demonstrated its potential of being a predictor of how well cancer patients are responding to chemotherapy.

By | April 18th, 2016|Medical publications|0 Comments

Chronix Biomedical to present clinical data on its cell-free DNA approach as an early predictor of response to chemotherapy at the AACR Annual Meeting

Howard B. Urnovitz, Ekkehard Schutz, et al. Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers AACR, 19 April 2016

Tumor cell-free DNA (cfDNA) has the potential to provide minimally invasive patient specific biomarkers to monitor tumor burden. Gains and losses of chromosomal regions - as a hallmark of cancer - have been detected in plasma as copy number aberrations (CNAs), and for several cancers a relation to tumor size has been reported.

By | March 16th, 2016|Medical publications|0 Comments